NASDAQ:ZNTL Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free ZNTL Stock Alerts $11.88 -0.09 (-0.75%) (As of 05/31/2024 08:51 PM ET) Add Compare Share Share Today's Range$11.82▼$13.0050-Day Range$10.99▼$16.1352-Week Range$9.56▼$31.46Volume838,100 shsAverage Volume750,458 shsMarket Capitalization$843.84 millionP/E RatioN/ADividend YieldN/APrice Target$31.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zentalis Pharmaceuticals alerts: Email Address Zentalis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside166.6% Upside$31.67 Price TargetShort InterestBearish26.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 10 Articles This WeekInsider TradingSelling Shares$157,325 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.72) to ($3.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.55 out of 5 starsMedical Sector876th out of 924 stocksPharmaceutical Preparations Industry414th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingZentalis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageZentalis Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Zentalis Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted26.09% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverZentalis Pharmaceuticals has a short interest ratio ("days to cover") of 24.4, which indicates bearish sentiment.Change versus previous monthShort interest in Zentalis Pharmaceuticals has recently increased by 5.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZentalis Pharmaceuticals does not currently pay a dividend.Dividend GrowthZentalis Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZNTL. Previous Next 1.9 News and Social Media Coverage News SentimentZentalis Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Zentalis Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zentalis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $157,325.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Zentalis Pharmaceuticals is held by insiders.Read more about Zentalis Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($2.72) to ($3.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zentalis Pharmaceuticals is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zentalis Pharmaceuticals is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZentalis Pharmaceuticals has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zentalis Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyI’m afraid WWIII is a very real possibility As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film.Take a look. About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More ZNTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZNTL Stock News HeadlinesJune 1 at 9:23 AM | insidertrades.comInsider Selling: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) CFO Sells 9,597 Shares of StockMay 10, 2024 | insidertrades.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Diana Hausman Sells 3,356 SharesJune 2 at 6:42 AM | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) CFO Sells $114,972.06 in StockMay 30, 2024 | americanbankingnews.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading 4.3% Higher May 30, 2024 | globenewswire.comZentalis Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of DirectorsMay 26, 2024 | americanbankingnews.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.28May 23, 2024 | globenewswire.comZentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual MeetingMay 14, 2024 | globenewswire.comZentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation SummitMay 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)May 9, 2024 | markets.businessinsider.comBuy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug TrialsMay 9, 2024 | markets.businessinsider.comBuy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of AzenosertibMay 8, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals StockMay 7, 2024 | finance.yahoo.comZentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...May 7, 2024 | globenewswire.comZentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational ProgressMay 2, 2024 | ca.finance.yahoo.comZentalis Pharmaceuticals, Inc. (ZNTL)May 1, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 13, 2024 | investing.comZentalis Pharmaceuticals CFO Melissa Epperly steps downApril 12, 2024 | seekingalpha.comZentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball RollingApril 11, 2024 | marketwatch.comZentalis Shares Fall After Chief Financial Officer ResignsApril 10, 2024 | investing.comZentalis Pharmaceuticals Llc (ZNTL)April 2, 2024 | globenewswire.comZentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024April 1, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 11, 2024 | finance.yahoo.comZNTL Jul 2024 12.500 callMarch 10, 2024 | finance.yahoo.comZNTL Jul 2024 10.000 callSee More Headlines Receive ZNTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/03/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZNTL CUSIPN/A CIK1725160 Webwww.zentalis.com Phone212-433-3791FaxN/AEmployees124Year FoundedN/APrice Target and Rating Average Stock Price Target$31.67 High Stock Price Target$50.00 Low Stock Price Target$15.00 Potential Upside/Downside+166.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-292,190,000.00 Net MarginsN/A Pretax Margin-507.56% Return on Equity-46.05% Return on Assets-37.80% Debt Debt-to-Equity RatioN/A Current Ratio9.19 Quick Ratio9.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.46 per share Price / Book1.84Miscellaneous Outstanding Shares71,030,000Free Float66,693,000Market Cap$843.84 million OptionableOptionable Beta1.82 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Kimberly Lynn Blackwell M.D. (Age 55)CEO & Director Comp: $1.17MMr. Cameron S. Gallagher M.B.A. (Age 54)Co-Founder, President, Interim CFO, Interim Treasurer & Director Comp: $892.15kMs. Andrea Paul J.D. (Age 43)Chief Legal Officer & Corporate Secretary Comp: $682.47kDr. Diana F. Hausman M.D. (Age 61)Chief Medical Officer & Director Comp: $38.44kMr. Vincent Vultaggio (Age 41)VP of Finance & Interim Principal Accounting Officer Dr. Mark Lackner Ph.D. (Age 56)Chief Scientific Officer Ms. Kimberly FreemanChief Strategy OfficerDr. Kyle Rasbach Ph.D. (Age 44)Pharm.D., Chief Business Officer Dr. Adrian Jubb M.D.Ph.D., Executive Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDCryoportNASDAQ:CYRXIGM BiosciencesNASDAQ:IGMSPrelude TherapeuticsNASDAQ:PRLDKura OncologyNASDAQ:KURAView All CompetitorsInsiders & InstitutionsCam GallagherSold 9,597 sharesTotal: $114,972.06 ($11.98/share)Opaleye Management Inc.Bought 200,000 shares on 5/29/2024Ownership: 0.282%California State Teachers Retirement SystemSold 3,222 shares on 5/16/2024Ownership: 0.071%Kennedy Capital Management LLCBought 11,978 shares on 5/16/2024Ownership: 0.017%Price T Rowe Associates Inc. MDBought 585,644 shares on 5/15/2024Ownership: 4.913%View All Insider TransactionsView All Institutional Transactions ZNTL Stock Analysis - Frequently Asked Questions Should I buy or sell Zentalis Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ZNTL shares. View ZNTL analyst ratings or view top-rated stocks. What is Zentalis Pharmaceuticals' stock price target for 2024? 7 Wall Street analysts have issued twelve-month target prices for Zentalis Pharmaceuticals' stock. Their ZNTL share price targets range from $15.00 to $50.00. On average, they predict the company's stock price to reach $31.67 in the next year. This suggests a possible upside of 166.6% from the stock's current price. View analysts price targets for ZNTL or view top-rated stocks among Wall Street analysts. How have ZNTL shares performed in 2024? Zentalis Pharmaceuticals' stock was trading at $15.15 at the beginning of 2024. Since then, ZNTL stock has decreased by 21.6% and is now trading at $11.88. View the best growth stocks for 2024 here. When is Zentalis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our ZNTL earnings forecast. How were Zentalis Pharmaceuticals' earnings last quarter? Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) issued its quarterly earnings results on Tuesday, May, 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.91. The company earned $40.56 million during the quarter, compared to the consensus estimate of $35 million. During the same quarter in the previous year, the company earned ($1.07) EPS. What other stocks do shareholders of Zentalis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Phillips 66 (PSX). When did Zentalis Pharmaceuticals IPO? Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Zentalis Pharmaceuticals' major shareholders? Zentalis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.19%), Price T Rowe Associates Inc. MD (4.91%), Opaleye Management Inc. (0.28%), Commonwealth Equity Services LLC (0.09%), California State Teachers Retirement System (0.07%) and Wealth Enhancement Advisory Services LLC (0.06%). Insiders that own company stock include Alexis Pinto, Anthony Y Sun, Cam Gallagher, Carrie Brownstein, David Michael Johnson, Diana Hausman, Dimitris Voliotis, Jan Skvarka, Kevin D Bunker, Kevin D Bunker, Kimberly Blackwell, Matrix Capital Management Comp and Melissa B Epperly. View institutional ownership trends. How do I buy shares of Zentalis Pharmaceuticals? Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZNTL) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch GoldPrepare for a Recession Unlike Any OtherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.